Mabrouka Doghman-Bouguerra, Pascal Finetti, Nelly Durand, Ivy Zortéa S. Parise, Silviu Sbiera, Giulia Cantini, Letizia Canu, Ségolène Hescot, Mirna M. O. Figueiredo, Heloisa Komechen, Iuliu Sbiera, Gabriella Nesi, Angelo Paci, Abir Al Ghuzlan, Daniel Birnbaum, Eric Baudin, Michaela Luconi, Martin Fassnacht, Bonald C. Figueiredo, François Bertucci, Enzo Lalli

• The SF-1 transcription factor target gene FATE1 encodes a cancer-testis antigen that has an important role in regulating apoptosis and response to chemotherapy in adrenocortical carcinoma (ACC) cells. Autoantibodies directed against FATE1 were previously detected in patients with hepatocellular carcinoma. In this study, we investigated the prevalence of circulating anti-FATE1 antibodies in pediatric and adult patients with adrenocortical tumors using three different methods (immunofluorescence, ELISA and Western blot). Our results show that aThe SF-1 transcription factor target gene FATE1 encodes a cancer-testis antigen that has an important role in regulating apoptosis and response to chemotherapy in adrenocortical carcinoma (ACC) cells. Autoantibodies directed against FATE1 were previously detected in patients with hepatocellular carcinoma. In this study, we investigated the prevalence of circulating anti-FATE1 antibodies in pediatric and adult patients with adrenocortical tumors using three different methods (immunofluorescence, ELISA and Western blot). Our results show that a pervasive anti-FATE1 immune response is present in those patients. Furthermore, FATE1 expression is a robust prognostic indicator in adult patients with ACC and is associated with increased steroidogenic and decreased immune response gene expression. These data can open perspectives for novel strategies in ACC immunotherapy.…